anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Before initiation of the program, participants in the personalized ICBT group will collaboratively work with the Guide to determine which modules of the ICBT program best meet the participant's needs/goals. The ICBT program contains a total of 21 modules. Once modules have been selected, the Guide will develop a personalized program for the participant. The participant will then be enrolled into the personalized program. Participants in this group will receive guided support by video chat or phone each week (based on participant's preference) by a trained Guide over the 8-week duration of the program. Weekly contact will include motivating participants to complete the weekly lessons and assistance on the practicing/application of the skills. The Guide will spend approximately 10-15 minutes per week with each participant.
An apparatus for dehydrating a liquid sample of biological material has a microwave waveguide that is open to the atmosphere. It has a microwave generator, means for introducing a container of the material into the waveguide, means for evacuating the container, means for rotating the container and means for removing the container from the waveguide. It can include means for moving the container through the waveguide and for sealing it. In a dehydration method, a container of the liquid sample is put into the open waveguide, evacuated, rotated at high speed and microwaved. The container of dehydrated material is then removed from the waveguide. The apparatus and method are particularly suitable for dehydrating vaccines.
PROBLEM TO BE SOLVED: To obtain the subject composition having excellent cleansing power capable of removing dirt from the bare skin surface and effects each of prevention of skin deterioration, degerming and bacteriostasis of the skin and deodorization, and stably exerting these effects for many hours by including an effective amount of tea extract in a deoxidized pure water. SOLUTION: This composition is obtained by including an effective amount of tea extract such as catechin, preferably at 20 mg/L to 1.0 wt.%, in pure water deoxidized so as to bring the dissolved oxygen concentration thereof in the composition at 25 deg.C and under 1 atmospheric pressure to preferably <=1.0 mg/L. It is preferable to include, in addition, an effective amount of an acidic antioxidative substance such as vitamin C in this composition. The oxidation-reduction potential of this composition is preferably negative. This composition is applied by spraying on the skin in order to e.g. clean the skin, get a refreshing feeling, wipe the hip of a baby.
This is a open-label study with only one treatment experimental arm. The patients will be treated, in a weekly basis, with 30 mg/m2 of cisplatino plus 65 mg/m2 of irinotecán (one cycle), until a total of 16 cycles.
Once determined eligible and provided consent, participants will be assigned in a randomized, double-blind, placebo-controlled, crossover fashion. Eligible study participants will complete one of four testing conditions. For each testing condition, study participants will arrive in the lab after observing an overnight fast. Upon arrival, participants will donate the first of six venous blood samples. Follow-up blood samples will be collected at 20, 40, 60, 90, and 120 minutes. All collected samples will be collected into two, 4mL EDTA tubes and have aliquots of 600 ul of plasma isolated and frozen at -80 degrees celsius. Collected plasma will be analyzed for changes in berberine, glucose, and insulin. Participants will observe a minimum of 72 hours washout between conditions
Physical Training will consist of each functional domain (balance, mobility, strength, and endurance) according to patients' functional levels. These will include static and dynamic balance training, mobility training, functional strength training focused on lower extremities, and endurance training as sustained walking. A daily 30 min session during the hospitalization will be performed with one-on-one supervision when as soon as hemodynamic stability is provided.
This is a stepped wedge of cross-over type. Patients included at each "step" are different individuals. The first "step" is a reference measurement where none of the clusters will implement the intervention. The investigating sites will be randomly drawn to determine the order in which they will implement the intervention, by "steps" of two months. A total of 10 patients by step are to be included in each center; these 10 patients must be regularly included along the 2-month period of each step. If 10 patients are already included before the end of the 2 months' step period, the center has to stop the inclusions till the beginning of the subsequent step. If a center, near to the end of a step, is far from reaching of the 10 patients' inclusion, it must increase the speed of its inclusions to be as close as possible of 10 patients included at the end of the step. In each center, patient sample has to be representative of type of cancer managed in the center, along the trial duration. The repartition of cancer types must be homogeneous along the steps and during the trial duration.

All participating investigating sites will have study collaborators in charge of organizing intervention implementation and data collection. The intervention will be prepared prior to the start of the trial, so that each investigating site can implement it as defined by the randomisation. Each center engaged to participate needs to participate till the end of the trial. A center commitment to participate will be requested before each center involvement to avoid center withdrawal after the start of the trial. Quantitative data regarding the HolisTM GV home app usage will be collected at each step and in each cluster by study collaborators, from the beginning of GERONTE system implementation. Care outcome data (Quality of life, anxiety, autonomy, additional hospitalisation, mortality...) will be collected by local referents at 3, 6, 9 and 12 months after inclusion in GERONTE. The data necessary to calculate the real cost of the intervention, of its implementation and of resource use data of patient management will be continuously collected during follow-up. GERONTE patient-centered system implementation and usage will be collected by the local referents in each center. Qualitative analysis will be performed in each center at GERONTE system implementation and during follow-up.
PURPOSE:To obtain a new peptide, having a specific amino acid sequence, capable of manifesting the inhibitory activity against angiotensin-converting enzymes and useful as an agent for promoting nutrition, a healthy food, a hypotensive agent, etc., capable of suppressing the blood pressure elevation by treating a peptide obtained from fish meat with a resin. CONSTITUTION:A fresh sardine is treated with a deboner to collect meat. The resultant fish meat is then divided into ground meat, quick-frozen at <=-30 deg.C and pulverized with a pulverizer. Water is added thereto and heating is carried out at 100 deg.C for 10min to inactivate an autolytic enzyme. The pH thereof is subsequently regulated to 10.0 and an alkaline protease is added. The resultant meat is kept at 45 deg.C for 17hr to carry out the enzymic hydrolysis. A filtration aid is subsequently added to perform the filtration treatment. Thereby, a peptide stock solution is obtained and then subjected to treatment with active carbon, subsequently concentrated under reduced pressure and subjected to gel filtration to discharge an active fraction to an ODS resin column. The adsorbed substance is then eluted with an aqueous solution of ethanol to afford the objective new peptide having an amino acid sequence such as Ala-Lys-Lys, Gln-Val-Lys, Gin- Val-Lys or/and Gly-Val-Lys.
The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.
Warning labels on tobacco products convey the health risks and discourage use. Warnings are even more effective when they contain images that depict the health consequences. However, little is known about the impact of cigarillo warnings, including pictorial warnings, on consumer behavior. The Experimental Tobacco Marketplace (ETM) task examines the effects of regulations on tobacco purchasing in the context of a complex tobacco marketplace. This project aims to address the gap in the knowledge about cigarillo risk communication by providing information on best practices for cigarillo warnings. Identifying effective cigarillo warnings is important to inform policy and guide research on effectively communicating risk to ultimately decrease use and tobacco-related morbidity and mortality.
The intervention group will receive 25-29 home visits during pregnancy and the first 2 years of life conducted by child health nurses. The frequency of home visits will be determined by nurses based on the needs of the families. The content of each home visit is individually tailored to the mother's needs, skills, strengths, and capacity using parenting education materials.
Administration of piperacillin-tazobactam as standard care therapy (4x 4g/d). Blood sampling in early and steady state dose (up to 5 samplings per dose). Collection of hemocultures, urine samples and sputum samples when possible.
OBJECTIVE: To examine the fear of negative evaluation as a predictor, and to explore the association of social anxiety with psychological correlates among women with polycystic ovaries.
METHODS: The cross-sectional study was conducted from August 2020 to November 2021 after approval form the University of Central Punjab, Lahore, Pakistan, and comprised unmarried women aged 18-26 diagnosed with polycystic ovary syndrome. The sample was raised from different clinics and hospitals based in Lahore and Gujranwala cities. The sample was divided into obese, hirsutism and acne vulgaris groups. Data was collected using a demographic proforma along with standardised Derriford Appearance Scale, Brief Fear of Negative Evaluation Scale, University of California, Los Angeles, Loneliness Scale and the Social Interaction Anxiety Scale. Data was analysed using SPSS 24.
RESULTS: Of the 180 patients, 60(33.3%) were in each of the 3 groups. The overall mean age was 21.4+/-2.27 years. A significant association of fear of negative evaluation was found with appearance distress, social anxiety and loneliness (p<0.05). The fear of negative evaluation and appearance distress also significantly predicted loneliness in the subjects (p<0.01). The obese group scored significantly higher in terms of fear of negative evaluation and social anxiety compared to the other groups (p<0.05).
CONCLUSION: Women with polycystic ovaries were found to be suffering from adverse psychological outcomes and social anxiety.
The present invention discloses a kind of oral and external applied medicine containing Ampelopsis cantoniensis （Hook. et Arn.） Planch. var. grossedentata Hand.-Mazz. treatment hepatitis, belongs to the technical field of Chinese herbal medicine processing.Ampelopsis cantoniensis （Hook. et Arn.） Planch. var. grossedentata Hand.-Mazz., Channa argus, Caulis Spatholobi, Herba Fici Simplicissimae, Herba Salviae Chinensis, Herba Artemisiae Scopariae, Fructus Liquidambaris, Folium et Cacumen Artemisiae Halodendri seed and EM original solution etc. is used to be prepared from.Channa argus removing toxic substances is reduced phlegm and internal heat, row water eliminating dampness by diuresis, the yin nourishing of strong sun, not only had additional nutrients but also the preventing and treating of suitable hepatitis, Caulis Spatholobi relaxing muscles and tendons to promote blood circulation nourishing blood for regulating menstruation, be suitable for hepatitis supplemental blood, compatibility Ampelopsis cantoniensis （Hook. et Arn.） Planch. var. grossedentata Hand.-Mazz. is inducing diuresis and reducing edema, has the effect that anti-inflammatory and antalgic protects the liver, 3 medicines to share the core drug into the damp and hot hepatitis for the treatment of.Herba Artemisiae Scopariae clearing away heat-damp and promoting diuresis removing toxic substances and promoting subsidence of swelling, blood circulation promoting and blood stasis dispelling, Herba Salviae Chinensis, Herba Fici Simplicissimae invigorating the spleen for eliminating dampness, benefiting QI for strengthening the superficies, regulating qi to disperse stagnation pain relieving, Fructus Liquidambaris is beneficial to dredge irritability, and all medicine compatibilities constitute the actual effect accessory drugs for the treatment of hepatitis for symptom.
Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure2,3 requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 30- mcg cephalothin to test the susceptibility of microorganisms to cephalexin.

Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30-mcg cephalothin disk should be interpreted according to the following criteria:

Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for cephalexin. 

As with standard dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 30- mcg cephalothin disk should provide the following zone diameters in these laboratory test quality control strains:
Participants who have not received Moderna COVID-19 vaccine or any other COVID-19 vaccine as of the index date of their matched vaccinated participant and who meet eligibility criteria will be included in this cohort. Participants will be followed up through EHR for occurrence of COVID-19 outcomes until the end of the study period, or censoring events (termination of KPSC membership allowing for a 31-day gap, death, receipt of a COVID-19 vaccine).
Around 25% of children are reported to have some degree of feeding issues of whom 3-10% have more severe feeding disorders1. Many of these feeding issues and difficulties can also lead to a need for supplemental nutrition in a child's diet due to the impact on growth. Those requiring supplemental nutrition may find themselves having to be fed using tube feedings (TF), which carries its own set of obstacles and factors to consider. While feeding problems have been estimated to occur in 25%-35% of children observed as exhibiting normal growth, that number may spike to 85% in those with GI-related growth disorders2. This highlights the need to ensure treatment plans and programs are in place to assist this patient population.

At Children's Mercy Hospital, GI specialists care for children who have a variety of conditions, caring for the whole child and addressing physical, mental, emotional, and social aspects. By using a combined approach, and promoting research that seeks to improve care, significant improvements in children's health have been reported. One specialty this has been evident in at Children's Mercy is the cardiac patient population. There have been improvements in growth, feedings, and timeliness of interventions seen with the use of CHAMP® App in the single ventricle population (a statistically significant difference in the frequency of growth failure, with no patients having growth failure during CHAMP use)3-4. By harnessing the experience and knowledge gained through the CHAMP® App research study, there is a great potential for children suffering from GI conditions to also benefit from this form of remote patient management and monitoring, especially when it comes to treating children with supplemental nutrition needs. There are no known Gastroenterology- Feeding mobile health software platforms with a dedicated research repository in pediatrics.
Reconstruction of the neurovascular unit is essential for the repair of spinal cord injury (SCI). Nonetheless, detailed documentation of specific vascular changes following SCI and targeted interventions for vascular treatment remains limited. This study demonstrates that traumatic pathological vascular remodeling occurs during the chronic phase of injury, characterized by enlarged vessel diameter, disruption of blood-spinal cord barrier, endothelial-to-mesenchymal transition (EndoMT), and heightened extracellular matrix deposition. After SCI, osteopontin (OPN), a critical factor secreted by immune cells, is indispensable for early vascular regeneration but also contributes to traumatic pathological vascular remodeling. This work further elucidates the mechanism by which OPN influences spinal cord microvascular endothelial cells, involving Akt-mediated Foxo1 phosphorylation. This process facilitates the extranuclear transport of Foxo1 and decreases Smad7 expression, leading to excessive activation of the TGF-β signaling pathway, which ultimately results in EndoMT and fibrosis. Targeted inhibition of Foxo1 phosphorylation through an endothelium-specific aptamer-liposome small molecule delivery system significantly mitigates vascular remodeling, thereby enhancing axon regeneration and neurological function recovery following SCI. The findings offer a novel perspective for drug therapies aimed at specifically targeting pathological vasculature after SCI.
The present invention relates to a cosmetic composition for regeneration, alleviation and stimulus relief of skin containing complex-fermented extract of Impatiens balsamina L., Rosae multiflorae fructus, Lepidium meyenii walpers, Eriobotrya japonica lindl. leaf, and Pachyrrhizus erosus root, and more specifically, to a cosmetic composition having an excellent effect of regeneration, alleviation and stimulus relief of skin by containing a complex-fermented extract of Impatiens balsamina L., Rosae multiflorae fructus, Lepidium meyenii walpers, Eriobotrya japonica lindl. leaf, and Pachyrrhizus erosus root manufactured by fermenting the Impatiens balsamina L., Rosae multiflorae fructus, Lepidium meyenii walpers, Eriobotrya japonica lindl. leaf, and Pachyrrhizus erosus root with Aureobasidium pullulans. The complex-fermented extract of the Impatiens balsamina L., Rosae multiflorae fructus, Lepidium meyenii walpers, Eriobotrya japonica lindl. leaf, and Pachyrrhizus erosus root according to the present invention uses natural plant materials and maximizes the activities via a fermentation process, thereby expressing safe and excellent effects on regeneration, alleviation and stimulus relief of skin to be valuably usable as natural cosmetics.
The present invention relates to biomarkers associated with the clinical response of FGF-18 compounds prior to or during the treatment of cartilage diseases. In particular, the invention relates to specific proteins in blood, serum, synovial fluid or urine that can be used for the diagnosis and treatment of cartilage disorders. Also disclosed are specific proteins involved in the cartilage response to FGF-18 compound treatment and diagnostic tools and kits based on the expression profiles of these proteins. Thus, the present invention can be used to predict the effect of treatment with an FGF-18 compound prior to or during the start of treatment with FGF-18. It can be used to select/identify subjects that can be treated with an intra-articular administration of an FGF-18 compound. Use of these biomarkers for diagnosis may increase subject benefit and decrease risk.
Patients receive sorafenib tosylate PO twice daily on days 1-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Chronic kidney disease (CKD) is considered a global public health problem, which affects approximately 10% of the world population. Due to partial or total loss of kidney function, the patient needs renal replacement therapy, with hemodialysis (HD) being the therapy most used, having a prevalence of up to 93.1% in Brazil. The restrictions imposed by CKD and the treatment of prolonged HD negatively affect health, increasing stress and decreasing the quality of life (QoL). The restrictions imposed by CKD and the treatment of prolonged HD negatively affect health, increasing stress and decreasing the QoL. Hemodialysis supports life and relieves a series of symptoms; however, it imposes many limitations. Social, financial and family stressors are numerous when dealing with the symptoms of the disease, restrictions and treatment prescriptions. Research shows positive results from Mindfulness-Based Interventions (MBIs) in reducing symptoms of different chronic diseases and mental and physical disorders such as: depression, anxiety, hypertension, cancer, chronic pain, cardiovascular diseases, insomnia, addictive behaviors, and kidney disease, and in improving medication adherence. This is an incipient field of research at the international level and almost nonexistent in Brazil. Evidence indicates the need for MBIs to be performed during HD sessions, adapted to the context, to facilitate patient compliance, contribute to the management of the discomfort generated during HD and promote health. This project has as main objectives to develop and evaluate the effects of a mindfulness-based intervention in the reduction of stressors, pain and quality of life of people undergoing hemodialysis. For this purpose, a randomized controlled pragmatic study with random allocation and blinding of the outcome evaluator will be performed, using quantitative and qualitative measures evaluated within 6 months after the intervention. The results of this research could form a consistent basis for a new and promising field of research that could contribute to improving the health of people undergoing hemodialysis and other populations that need long-term hospital care.
The side effects of irbesartan are generally rare and apparently independent of dose; those of hydrochlorothiazide are a mixture of dose-dependent (primarily hypokalemia) and dose-independent phenomena (e.g., pancreatitis), the former much more common than the latter. [See Adverse Reactions (6).] 

Maximum antihypertensive effects are attained within 2 to 4 weeks after a change in dose.

Irbesartan and hydrochlorothiazide tablets may be administered with or without food.

Irbesartan and hydrochlorothiazide tablets may be administered with other antihypertensive agents.

Renal Impairment. The usual regimens of therapy with irbesartan and hydrochlorothiazide tablets may be followed as long as the patient's creatinine clearance is >30 mL/min. In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so irbesartan and hydrochlorothiazide tablets are not recommended. 

Hepatic Impairment. No dosage adjustment is necessary in patients with hepatic impairment.
The patients are treated with traditional Chinese medicine. They take 150ml of liquid medicine every morning and evening for 7 days.
PURPOSE:To obtain a preventing and therapeutic agent, containing a tripeptide as an active ingredient, having lowering action on the blood calcium level and useful for osteopathy such as malignant hypercalcemia, bone Behcet diseases or osteoporosis. CONSTITUTION:The objective preventing and therapeutic agent is obtained by including a compound expressed by the formula R-Leu-Leu-Xaa-H (R is acetyl or benzyloxycarbonyl; Leu is leucine residue; Xaa is methionine residue, leucine residue or norleucine residue; H is residue in which C-terminal carboxyl group is reduced to an aldehyde), e.g. N-acetyl-leucyl-leucyl-leucinal as an active ingredient. This agent can be formulated into a dosage form such as a capsule, a tablet, a granule, a fine granule, a syrup, an injection, a suppository, a vaginal suppository, a spray, an ointment or a tape. The dose for an adult is 0.1-1000mg/kg body weight per day. Thereby, reduction in both calcium salts and collagen fiber in bones is suppressed.